China
Africa
Explore chapters and articles related to this topic
Molecular-Imprinting-Based Sensors
Published in Banshi Dhar Gupta, Anand Mohan Shrivastav, Sruthi Prasood Usha, Optical Sensors for Biomedical Diagnostics and Environmental Monitoring, 2017
Banshi Dhar Gupta, Anand Mohan Shrivastav, Sruthi Prasood Usha
Till now, we have discussed the fundamentals, types, and various approaches for the synthesis of MIPs. In this section, we shall discuss the role of MIPs in various applications especially in sensing. As mentioned earlier, an effective MIP has several advantageous properties such as highly specific template recognition, high-adsorption ability, fast binding–unbinding kinetics, homogeneous particle size, good imprinting efficiency, and much more. These properties make MIP play an effective role in various applications of extraction, separation, purification, assay formation, and sensing. These roles are summarized in Figure 6.5.
Immunotherapy approach with recombinant survivin adjuvanted with alum and MIP suppresses tumor growth in murine model of breast cancer
Published in Preparative Biochemistry and Biotechnology, 2018
Himani Garg, Jagdish C. Gupta, G. P. Talwar, Shweta Dubey
Although tremendous progress has been made in developing potent adjuvants, yet most of them have not been successful because of toxicity, bioavailability, cost, or lack of induction of desired immune response.[12] So far, alum is the only adjuvant approved for human use. However, alum does not initiate a robust Th1 cell-mediated immune response.[26] We therefore, supplemented the immunogenicity of recombinant survivin with alum and MIP as an additional adjuvant. MIP has been shown to enhance innate signaling, induce dendritic cell (DC) activation, and enhance antigen presentation.[27] Hence, we propose that combining full-length recombinant survivin with MIP enhances innate signaling and targets antigen to dendritic cells. This adjuvant combination may, therefore, generate epitopes for activation of antigen-specific CD8 and CD4 T cell response and humoral immune response as well. MIP also has been found to be nonpathogenic and safe for human application in tuberculosis, HIV, and psoriasis.[282930] Our data indicate that MIP may be further explored as potent adjuvant for other recombinant tumor antigens. Since both alum and MIP are already approved for human use, therefore, the development time for this combination therapy may not be very long. Our data suggest that increasing antigen dose in the combination from 5 to 10 µg led to a greater increase in tumor growth inhibition. The immunization schedule used in our study also suggests that repeated immunization with combination was able to induce a long-term protective effect.